• Search
  • Helpdesk
  • Sales contact
Get your demo

How Kayentis reduces the CO2 emissions of your eCOA projects with its carbon neutral program

CSR
Last updated: October 24, 2025

In 2020, we implemented a carbon neutral program for all our clinical trials.
Our goal? To reduce project CO2 emissions without impacting cost, quality or timelines.

Download the infographic
Ask for more information
Follow us on social media
Subscribe to our newsletter
You may also like

ePRO in early phase oncology trials: A revolution on the...

Patient-Reported Outcomes in early-phase oncology clinical trialsA Stepping Stone to...

Answering the Sustainability Call: Digital Health Technologies and eCOA

Kayentis secures Silver Medal in EcoVadis sustainability evaluation with significant...

Engage patients throughout the clinical trial journey

Rethinking Phase 1 Oncology Trials with Electronic Patient-Reported Outcomes

About the author
Picture of Marc Chaperon

Marc Chaperon

Estelle brings 20+ years of experience in pre-clinical and clinical research from Top 5 Pharma and Biotech firms. Leading projects across Phases 1 to 4 in diverse therapeutic areas, she offers deep insights into clinical science, operations, and regulatory intricacies. Appointed as Chief Medical Officer at Kayentis in May 2019.
Meet us at the following events

PCMG AI Symposium 2025

NOV 24, 2025 • London, UK
PCMG AI Symposium 2025